Details for Patent: 9,629,841

Which drugs does patent 9,629,841 protect, and when does it expire?

Patent 9,629,841 protects VIEKIRA PAK (COPACKAGED) and is included in one NDA.

This patent has sixteen patent family members in ten countries.

Summary for Patent: 9,629,841

Title:	Formulations of pyrimidinedione derivative compounds
Abstract:	The present disclosure relates to pharmaceutical compositions of pyrimidinedione derivative compounds and methods of preparing and uses thereof. The disclosure also relates to methods of enhancing bioavailability of pyrimidinedione derivative compounds in pharmaceutical compositions administered to a subject and methods of reducing the amount of a pyrimidinedione derivative compound in a pharmaceutical composition while achieving the same bioavailability in a subject.
Inventor(s):	Li; Yanxia (Libertyville, IL), Gao; Ping (Highland Park, IL), Shi; Yi (Libertyville, IL), Zhang; Geoff G. (Vernon Hills, IL), Goa; Yi (Vernon Hills, IL), Wu; Jianwei (Potomac, MD)
Assignee:	AbbVie Inc. (North Chicago, IL)
Application Number:	14/058,071
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound; Process; Dosage form;

Drugs Protected by US Patent 9,629,841

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	VIEKIRA PAK (COPACKAGED)	dasabuvir sodium; ombitasvir, paritaprevir, ritonavir	TABLET;ORAL	206619-001	Dec 19, 2014		DISCN	Yes	No			Y			TREATMENT OF HCV INFECTION USING DASABUVIR

International Family Members for US Patent 9,629,841

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013330993
Brazil	112015008927
Canada	2888883
China	104853752
China	109260207
Eurasian Patent Organization	028481
Eurasian Patent Organization	032913